MARY ZUTTER, MD
Medical Practice in Nashville, TN
License number
Tennessee MD37685
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
3601 Tvc, Nashville, TN 37232
Phone
(615) 322-3000
Personal information
See more information about MARY ZUTTER at radaris.comName
Address
Phone
7 Breckenridge, Nashville, TN 37215
7 Breckenridge, Nashville, TN 37215
Professional information
See more information about MARY ZUTTER at trustoria.com
Dr. Mary Zutter, Nashville TN - MD (Doctor of Medicine)
Dr. Mary Zutter, Nashville TN - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
DEPARTMENT OF RADIOLOGY VUMC
1161 21St Ave S, Nashville 37232
(615) 343-1501 (Phone)
Vanderbilt Univ Med Ctr Pathlgy
4605 The Vanderbilt Clinic, Nashville 37232
(615) 322-0126 (Phone)
1161 21St Ave S, Nashville 37232
(615) 343-1501 (Phone)
Vanderbilt Univ Med Ctr Pathlgy
4605 The Vanderbilt Clinic, Nashville 37232
(615) 322-0126 (Phone)
Certifications:
Anatomic & Clinical Pathology, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
DEPARTMENT OF RADIOLOGY VUMC
1161 21St Ave S, Nashville 37232
Vanderbilt Univ Med Ctr Pathlgy
4605 The Vanderbilt Clinic, Nashville 37232
Vanderbilt University Hospital
1211 Medical Center Dr, Nashville 37232
1161 21St Ave S, Nashville 37232
Vanderbilt Univ Med Ctr Pathlgy
4605 The Vanderbilt Clinic, Nashville 37232
Vanderbilt University Hospital
1211 Medical Center Dr, Nashville 37232
Education:
Medical School
Tulane University of Louisiana
Graduated: 1981
U Wash Affil Hosps
Fred Hutchinson Cancer Ctr-U Wash
Tulane University of Louisiana
Graduated: 1981
U Wash Affil Hosps
Fred Hutchinson Cancer Ctr-U Wash
Anti-Angiogenic Targets For Cancer Therapy
Anti-Angiogenic Targets For Cancer Therapy
US Patent:
2008026, Oct 30, 2008
Filed:
Aug 28, 2007
Appl. No.:
11/892964
Inventors:
Mary Zutter - Nashville TN, US
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241741, 4241721
Abstract:
The use of inhibitory anti-α2β1 integrin antibodies to inhibit tumor neoangiogenesis, slow tumor growth, treat abnormal angiogenesis, treat integrin-mediated disorders and inhibit endothelial cell proliferation.